Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ACTRIMS 2022 | ACTRIMS day 1 highlights with Jeffrey Cohen

Jeffrey Cohen • 24 Feb 2022
ACTRIMS 2022
Multiple Sclerosis and Related Disorders

Jeffrey A. Cohen, MD, Cleveland Clinic, Cleveland, OH, comments on exciting topics discussed during the first day of the ACTRIMS Forum 2022. Themed ‘Biomarkers in MS’, the meeting has generated lots of discussion surrounding novel biomarkers for early diagnosis, prognostication, and predicting treatment response. Dr Cohen highlights rim lesions as a key area of progress, which may be a useful marker to incorporate into MS diagnostic criteria. This interview took place at the ACTRIMS Forum 2022 in West Palm Beach, Florida.

More from Jeffrey Cohen

1:09
Ozanimod: long-term safety and efficacy in relapsing MS
Jeffrey Cohen • 24 Feb 2022
1:35
ACTRIMS research priorities
Jeffrey Cohen • 24 Feb 2022
1:01
Unmet needs in multiple sclerosis
Jeffrey Cohen • 24 Feb 2022
1:13
How to approach MS treatment sequencing in a crowded therapeutic market
Jeffrey Cohen • 24 Feb 2022

Related Videos

3:44
Navigating intra-individual variability for early detection of cognitive decline
Leigh Charvet • 23 Feb 2024
5:42
Mapping the functional interactome in MS lesions to shed light on remyelination failure
Milos Opacic • 5 Mar 2024
3:26
Acupressure for the management of pain and anxiety in patients with MS
Megan Weigel • 4 Mar 2024
5:37
GAIT-HUB: a home-based gait monitoring system for patients with MS
Giuseppina Pilloni • 4 Mar 2024
The content of VJNeurology is intended for healthcare professionals